Shares of NovoCure Limited (NVCR) have witnessed a substantial 85% drop from their 52-week high of $95.91, recorded last February, and trade around $14.
The company is focused on the manufacture and commercialization of Tumor Treating Fields devices, designed to extend survival in some of the most aggressive forms of cancer. Its commercially available Tumor Treating Fields (TTFields) devices include Optune Gio and Optune Lua.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com